XML 14 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 17,514,213 $ 22,604,481
Supplies for clinical trials 1,321,604 1,158,632
Other assets 612,373 797,425
Total current assets 19,448,190 24,560,538
Property and equipment, net 164,567 180,922
Supplies for clinical trials 1,308,867 1,115,657
Deposits 3,762,878 4,176,280
Deferred financing costs 8,593 48,977
Total assets 24,693,095 30,082,374
Current liabilities:    
Accounts payable 920,030 1,161,258
Accrued compensation and benefits 215,408 790,487
Accrued liabilities 1,136,448 317,653
Total current liabilities 2,271,886 2,269,398
CIRM liability 4,398,732 4,133,905
Warrant liability 1,492,400 1,958,775
Total liabilities $ 8,163,018 $ 8,362,078
Commitments and contingencies (Note 5)
Shareholders’ equity:    
Common stock, $0.0001 par value; 249,000,000 shares authorized; 91,727,797 and 90,310,149 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively $ 9,173 $ 9,031
Additional paid-in capital 96,291,989 95,849,005
Accumulated deficit (79,771,085) (74,137,740)
Total shareholders’ equity 16,530,077 21,720,296
Total liabilities and shareholders’ equity $ 24,693,095 $ 30,082,374